Hyperlipidemia Drug Market Projected to Reach $24.9 Billion by 2035 Amid Innovations in Therapy

Hyperlipidemia drug market was valued at $18.4 billion in 2025 and is projected to reach $24.9 billion by 2035, growing at a CAGR of 3.1% during the forecast period (2026-2035). The global hyperlipidemia drug market is experiencing significant growth due to rising prevalence of high cholesterol and cardiovascular diseases. Innovations in drug therapies are providing more effective and targeted treatment options for patients. RNA interference (RNAi) therapies, such as inclisiran, reduce LDL cholesterol by silencing the PCSK9 gene, offering a novel mechanism of action. Next-generation PCSK9 inhibitors complement existing therapies with potent lipid-lowering effects. Fixed-dose combination drugs are being introduced to simplify treatment regimens and improve patient adherence. The market continues to expand as new therapies and treatment approaches improve long-term cholesterol management. Enhanced drug mechanisms and more convenient dosing options are contributing to wider adoption and sustained market growth. For instance, in July 2025, Novartis received FDA approval for a label update for Leqvio (inclisiran), allowing its use as monotherapy with diet and exercise to lower LDL-C in adults with hypercholesterolemia. The update removes the prior requirement to combine Leqvio with statin therapy. Leqvio’s twice-yearly, provider-administered dosing is positioned to support long-term LDL-C management and adherence among patients.

Browse the full report description of “Hyperlipidemia Drug Market Size, Share & Trends Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives and Others), by Route of Administration (Oral and Injectable / Parenteral) and by Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies / Ecommerce), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/hyperlipidemia-drug-market

Clinical studies indicate that these approaches contribute to more consistent cholesterol management and may lower cardiovascular risk. Regulatory approvals for broader indications have enabled wider integration of these therapies into clinical practice. Ongoing research continues to explore new molecular targets and delivery technologies to enhance treatment safety and efficacy. Overall, these developments are driving a shift toward more patient-centered and innovative management strategies in hyperlipidemia care.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Drug Class
• Route of Administration
• Distribution Channel
• Competitive Landscape – Pfizer Inc., Merck & Co. Inc., AstraZeneca Plc, Amgen Inc. and Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hyperlipidemia Drug Market Report Segment

By Product Type

• Disposable / Consumable Supplies
• Sterilization & Infection Control Supplies
• Diagnostic & Testing Supplies
• Surgical & Operating Room Supplies
• Patient Care & General Supplies

By End-User

• Hospitals & Clinics
• Ambulatory Surgical Centres
• Diagnostic Centres
• Nursing Facilities
• Others

Global Hyperlipidemia Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hyperlipidemia-drug-market